Cargando…

miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6)

To study the regulation of miR-148a-3p on CDK6 and its mechanism in the progress of acute myeloid leukemia (AML), differential miRNAs were analyzed by bioinformatics, and the miR-148a-3p levels in AML cell lines were detected. Results showed that miR-148a-3p played a crucial role in AML, and the lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Hong, Jia, Xiaofeng, Yang, Fan, Shi, Pengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806774/ https://www.ncbi.nlm.nih.gov/pubmed/34308752 http://dx.doi.org/10.1080/21655979.2021.1956400

Ejemplares similares

miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6
por: Xia, Bairong, et al.
Publicado: (2015)

miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells
por: Ghashghaei, Maryam, et al.
Publicado: (2022)

LncRNA HOTAIRM1 is involved in the progression of acute myeloid leukemia through targeting miR-148b
por: Hu, Ning, et al.
Publicado: (2019)

Expression of the miR-148/152 Family in Acute Myeloid Leukemia and its Clinical Significance
por: Wang, Xiao-Xue, et al.
Publicado: (2017)

miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
por: Hoareau-Aveilla, Coralie, et al.
Publicado: (2019)

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
por: Johnston, Stephen, et al.
Publicado: (2023)

miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels
por: Honeywell, D. Rice, et al.
Publicado: (2013)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6
por: Zhu, Kegan, et al.
Publicado: (2016)

miR-449a and CDK6 in gastric carcinoma
por: LI, LI-PING, et al.
Publicado: (2014)

miR‐148a suppresses inflammation in lipopolysaccharide‐induced endometritis
por: Jiang, Kangfeng, et al.
Publicado: (2019)

Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression
por: Liu, Yu, et al.
Publicado: (2022)

miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells
por: ZHANG, JING, et al.
Publicado: (2014)

Upregulation of miR-124-3p by Liver X Receptor Inhibits the Growth of Hepatocellular Carcinoma Cells Via Suppressing Cyclin D1 and CDK6
por: Zhong, Dan, et al.
Publicado: (2020)

Cyclin-dependent kinase 6 (CDK6) as a potent regulator of the ovarian primordial-to-primary follicle transition
por: Ataei-Nazari, S., et al.
Publicado: (2022)

miR-449a-5p suppresses CDK6 expression to inhibit cardiomyocyte proliferation
por: Li, Bing, et al.
Publicado: (2021)

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
por: Liu, Wei, et al.
Publicado: (2021)

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
por: Finn, Richard S., et al.
Publicado: (2016)

Cyclin-Dependent Kinase (CDK) Inhibitors: Structure–Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016)

The tumor-suppressive function of miR-1296-5p by targeting EGFR and CDK6 in gastric cancer
por: Jia, Yan, et al.
Publicado: (2019)

Circular RNA CDK6 suppresses cervical cancer proliferation and metastasis by sponging miR-449a
por: Zhong, Peilin, et al.
Publicado: (2022)

Therapeutic Delivery of miR-148a Suppresses Ventricular Dilation in Heart Failure
por: Raso, Andrea, et al.
Publicado: (2019)

Lineage specific composition of cyclin D–CDK4/CDK6–p27 complexes reveals distinct functions of CDK4, CDK6 and individual D‐type cyclins in differentiating cells of embryonic origin
por: Bryja, V., et al.
Publicado: (2008)

Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer
por: Gong, Wangang, et al.
Publicado: (2020)

The Role of Cyclin-Dependent Kinases (CDK) 4/6 in the Ovarian Tissue and the Possible Effects of Their Exogenous Inhibition
por: Scavone, Graziana, et al.
Publicado: (2023)

Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014)

miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met
por: Wang, Wen, et al.
Publicado: (2018)

miR-148 Regulates Mitf in Melanoma Cells
por: Haflidadóttir, Benedikta S., et al.
Publicado: (2010)

LncRNA SNHG12 regulates the radiosensitivity of cervical cancer through the miR-148a/CDK1 pathway
por: Wang, Chen, et al.
Publicado: (2020)

miR-96-5p Suppresses the Progression of Nasopharyngeal Carcinoma by Targeting CDK1
por: Luo, Xiaoqin, et al.
Publicado: (2020)

Nucleophosmin Phosphorylation by v-Cyclin-CDK6 Controls KSHV Latency
por: Sarek, Grzegorz, et al.
Publicado: (2010)

Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
por: Thill, Marc, et al.
Publicado: (2018)

The awakening of the CDK10/Cyclin M protein kinase
por: Guen, Vincent J., et al.
Publicado: (2017)

Long non-coding RNA LINC01018 inhibits the progression of acute myeloid leukemia by targeting miR-499a-5p to regulate PDCD4
por: Zhou, Hong, et al.
Publicado: (2021)

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
por: Ogata, Ryohei, et al.
Publicado: (2020)

MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
por: Yan, Jing, et al.
Publicado: (2016)

miR-148 family members are putative biomarkers for sepsis
por: Dong, Lei, et al.
Publicado: (2019)

Lnc HAGLR Promotes Colon Cancer Progression Through Sponging miR‐185‐5p and Activating CDK4 and CDK6 in vitro and in vivo
por: Sun, Weixuan, et al.
Publicado: (2020)

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
por: Yıldırım, Hasan Çağrı, et al.
Publicado: (2022)

miR-148b-3p, miR-190b, and miR-429 Regulate Cell Progression and Act as Potential Biomarkers for Breast Cancer
por: Dai, Wenzhu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vjp119b08dm20g1s4km4g8arod